Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
Evolent Health Inc (NYSE: EVH) closed the day trading at $4.96 down -17.33% from the previous closing price of $6.0. In other words, the price has decreased by -$17.33 from its previous closing price. On the day, 8.67 million shares were traded. EVH stock price reached its highest trading level at $6.28 during the session, while it also had its lowest trading level at $4.9235.
Ratios:
For a better understanding of EVH, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.33 and its Current Ratio is at 1.33. In the meantime, Its Debt-to-Equity ratio is 1.29 whereas as Long-Term Debt/Eq ratio is at 1.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Needham on January 10, 2025, initiated with a Buy rating and assigned the stock a target price of $15.
On December 03, 2024, BTIG Research reiterated its Buy rating and also upped its target price recommendation from $36 to $29.
Stephens Downgraded its Overweight to Equal-Weight on November 08, 2024, whereas the target price for the stock was revised from $38 to $16.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 06 ’25 when Holder Diane bought 2,735 shares for $9.33 per share. The transaction valued at 25,518 led to the insider holds 70,584 shares of the business.
McCarthy Daniel Joseph bought 11,040 shares of EVH for $99,470 on Mar 06 ’25. The PRESIDENT now owns 389,004 shares after completing the transaction at $9.01 per share. On Mar 07 ’25, another insider, Jelinek Richard M, who serves as the Director of the company, bought 30,000 shares for $9.12 each. As a result, the insider paid 273,750 and bolstered with 15,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EVH now has a Market Capitalization of 553500032 and an Enterprise Value of 1519165056. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.28 while its Price-to-Book (P/B) ratio in mrq is 0.66. Its current Enterprise Value per Revenue stands at 0.74 whereas that against EBITDA is 19.468.
Stock Price History:
The Beta on a monthly basis for EVH is 0.26, which has changed by -0.67217445 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, EVH has reached a high of $25.06, while it has fallen to a 52-week low of $5.97. The 50-Day Moving Average of the stock is -39.25%, while the 200-Day Moving Average is calculated to be -46.34%.
Shares Statistics:
Over the past 3-months, EVH traded about 3.05M shares per day on average, while over the past 10 days, EVH traded about 3362670 shares per day. A total of 117.51M shares are outstanding, with a floating share count of 114.24M. Insiders hold about 2.78% of the company’s shares, while institutions hold 109.12% stake in the company. Shares short for EVH as of 1760486400 were 17620752 with a Short Ratio of 5.78, compared to 1757894400 on 23098110. Therefore, it implies a Short% of Shares Outstanding of 17620752 and a Short% of Float of 15.379999999999999.
Earnings Estimates
The market rating of Evolent Health Inc (EVH) is currently shaped by the ongoing analysis conducted by 8.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.1, with high estimates of $0.17 and low estimates of $0.02.
Analysts are recommending an EPS of between $0.2 and $0.0 for the fiscal current year, implying an average EPS of $0.1. EPS for the following year is $0.53, with 10.0 analysts recommending between $0.78 and $0.41.
Revenue Estimates
12 analysts predict $471.23M in revenue for. The current quarter. It ranges from a high estimate of $477.2M to a low estimate of $466.2M. As of. The current estimate, Evolent Health Inc’s year-ago sales were $646.54MFor the next quarter, 12 analysts are estimating revenue of $554.49M. There is a high estimate of $608.14M for the next quarter, whereas the lowest estimate is $520.37M.
A total of 12 analysts have provided revenue estimates for EVH’s current fiscal year. The highest revenue estimate was $1.88B, while the lowest revenue estimate was $1.86B, resulting in an average revenue estimate of $1.87B. In the same quarter a year ago, actual revenue was $2.55BBased on 13 analysts’ estimates, the company’s revenue will be $2.4B in the next fiscal year. The high estimate is $2.53B and the low estimate is $2.18B.
